Plants are sources of interest in the search for novel antitumour agents. Reports in the literature suggest that substances in Eupatorium cannabinum L. (Asteraceae) possess such activity, although no systematic study on this subject is available as yet. This plant is native in most parts of Europe and contains several different sesquiterpene lactones. Eupatoriopicrin (EUP; Figure 1 ), a germacranolide, may be present up to 0.4% in the dried plant material (Rodriguez et al., 1976; .
Several studies have been performed with EUP using cultured cells (HIadof et al., 1975a,b; . One other report deals with four sesquiterpene lactones (Arrick et al., 1983) , not including EUP. Inhibition of tumour cell growth and cell lysis were the criteria of effectivity used in these investigations. No research is known on clonogenic ability of tumour cells after exposure to sesquiterpene lactones.
Reports on in vivo testing of EUP are extremely scarce. In this respect only one study is known, where it is mentioned that death of tumour bearing mice was delayed after administration of EUP (Hladon & Chodera, 1975) . Apart from this there are two preliminary reports from our own laboratories concerned with tumour growth delay studies after intraperitoneal (i.p.) administration of EUP, using tumour bearing mice (Woerdenbag et al., 1987a, b) .
Sesquiterpene lactones possessing an a-methylene y-lactone functionality (EUP: see Figure 1 ) are electrophilic agents and thus apt to react with biological nucleophiles, such as the sulphydryl group of glutathione (GSH) (Picman et al., 1979) , proteins and parts of DNA. In vitro high reactivity of some sesquiterpene lactones towards GSH in aqueous buffer has been described by Arrick et al. (1983) . Reduction of cellular GSH levels in vitro has been reported for tumour cells exposed to sesquiterpene lactones (Arrick et al., 1983) . In vivo a decrease of GSH levels in liver and tumour tissue of the mouse, after i.p. and intravenous (i.v.) administration, has been described by us (Woerdenbag et al., 1988b) .
It is of interest to explore further the potential of sesquiterpene lactones as antitumour agents in animal models. In the current study investigations are described on the effect of EUP on tumour cells grown in vitro using a clonogenic assay, and in vivo after i.v. injection, on two murine tumour models ( affected the cellular GSH content (Woerdenbag et al., 1988b) , it was decided to investigate whether chemosensitisation of EUP might take place in vitro and in vivo after depleting tumour cells and tissue of GSH by buthionine sulphoximine (BSO), a specific inhibitor of GSH synthesis, by reacting with y-glutamylcysteine synthetase (Griffith & Meister, 1979a (Mayo, 1972) , whereas the FIG 26 fibrosarcoma does not metastasize (Schlumberger, 1981; Woerdenbag et al., 1987b) . Both tumours were maintained by serial passage in C57B1 mice. The doubling time, Td. defined as the time necessary for a tumour to double its volume or weight, was derived from the growth curves, and was used to characterise tumour growth (Steel, 1977 (Woerdenbag et al., 1987a) . A total of 4 x 106 viable cells, in a volume of 0.2 ml, were transplanted subcutaneously in the left flank of the mice. The Lewis lung carcinoma was transplanted in female mice (passages 6-13); the fibrosarcoma FIO 26 in male mice (passages 6-10). Tumour growth was recorded by measuring the three orthogonal diameters of the tumour with a vernier caliper. Measurements were converted to volume using the geometrical formula V= 1/6r x length x width x thickness (Steel, 1977) . Drug treatment of the mice In the tumour growth delay experiments, drugs were administered at a tumour volume of 500 + 150 Ml, designated as 'day 0'. The Lewis lung carcinoma attained this volume about 14 days after transplantation, the FIO 26 after about 13 days. The mice were given 20 or 40mg kg-1 EUP i.v., with and without i.p. pretreatment of BSO at a dose of 4 mmol kg-1, 6 h before the EUP injection. BSO 4mmolkg-1 i.p. was also administered alone.
In the experiments monitoring the GSH status in liver and tumour tissue, the mice were treated at a tumour volume between 500 and 1,000pl. In this range of tumour volumes no difference was found in GSH content in the control animals or in the animals treated with EUP. EUP was dissolved in ethanol 96% (v/v) and diluted with 0.9% NaCl solution, yielding a final ethanol concentration of 10% (v/v). The injected volume was 0.1 ml per 10 g body weight (20 mg kg-1 i.v.) or 0.2 ml per lOg body weight (40mgkg-1 i.v.). All i.v. injections were in the tail vein, and delivered slowly. BSO was dissolved in 0.9% NaCl solution and injected i.p. at 0.15 ml per 10 g body weight. The solutions were prepared immediately before use. Control experiments were performed with the vehicle only. No sexdependent difference was found in tumour growth or in the response to the drugs injected. Preparation of tissue homogenates All steps to prepare tissue homogenates were carried out at 4°C. Mice were killed by cervical dislocation. The tumour and liver were excised and necrotic parts (if any) were removed from the tumour. Subsequently, the tumour and liver were washed with ice-cold 0.9% NaCl solution. The tissue was minced with scissors and a 10% homogenate in 0.9% NaCl solution was prepared using a Potter-Elvehjem homogeniser (liver) or a Dounce homogeniser (tumour). The homogenate was centrifuged (160g, 4°C, 5 min) and the supernatant was stored at -20°C until assayed for GSH and protein content (within 1 month). Biochemical assays Total gluftathione, referred to as GSH in this paper, was assayed according to Griffith (1980) , with GSSG as the standard. The thiol concentration was calculated on a protein basis, assayed by the method of Lowry et al. (1951) , with bovine serum albumin as the standard. Before performing the latter analysis, the thawed homogenate samples were sonicated (50 W, 30 s).
Statistics
For the statistical evaluation of the data from the in vitro study, the unpaired Student's t test was used. In the experiments monitoring tumour growth, statistically significant differences between the control group and the treated groups and between the differently treated groups were calculated by one-way analysis of variance (ANOVA) of the log-transformed data, followed by the Newman-Keuls test, according to Snedecor & Cochran (1980) . The doubling times of the tumours were analysed by use of Dunnett's test for multiple comparisons to a single mean (Dunnett, 1964 injection of 20 or 40 mg kg-I EUP. Compared with the control group, the Td(100%) increased significantly after these treatments. No difference in tumour response was found between 20 and 40 mg kg-1 EUP. As seen from the Td(100%) and the levels of significance, when the control and EUP treated groups are compared, the FIO 26 fibrosarcoma was more sensitive (P < 0.01) for treatment with EUP than the Lewis lung carcinoma (P < 0.05). Regarding cumulative tumour volumes, a significant difference (P < 0.05) with the control group was revealed up to 2 days after injection for the Lewis 
GSH reduction in vivo
The GSH levels in the tumours of the control groups were 33.4+5.6nmol per mg protein (mean+s.d., n=19) for the Lewis lung carcinoma and 54.6 + 5.6 nmol per mg protein (n = 13) for the FIO 26. The GSH status in the liver of the tumour bearing animals was respectively 83.6 + 10.9 and 78.2 + 9.9 nmol permg protein. Liver tissue of normal female C57B1 mice contained 71.4 + 9.4 nmol per mg protein (n = 9) and of normal male C57B1 mice 71.1 + 5.3 nmol GSH per mg protein (n = 7). So the livers especially of the Lewis lung bearing animals had an enhanced GSH content.
We will first consider the effect of BSO alone on the GSH level in liver and tumour tissue. Following i.p. injection with 4 mmol kg-1 BSO, the GSH level in liver ( Figure 6 ) and tumour ( Figure 7) tissue was reduced. The nadir was reached after 4-8 h in the liver and after 12 h in both tumours. The degree of GSH depletion was about 50% in livers of normal mice and mice bearing the FIO 26 tumour. The liver of the Lewis lung carcinoma bearing animals was depleted to about 85%. Maximal depletion was 65% for the Lewis lung tumour and 80% for the FIO 26 fibrosarcoma. A rapid restoration, 12 h after injection, was seen for normal livers and livers from FIO 26 bearing mice. The restoration of the GSH level in the liver of Lewis lung carcinoma bearing mice was slow and still incomplete after 48 h (P < 0.05 compared with the control). In both tumour types recovery of the GSH status started later.
Discussion
Eupatoriopicrin in vitro The studies reported here extend earlier observations that sesquiterpene lactones have cytotoxic properties. When the cytotoxicity is compared with the GSH reduction in FIG 26 cells, after 1 h GSH depletion to EUP, it can be concluded that significant GSH reduction began to occur with concentrations >1 pg ml-I (2.8 nmol ml -1) (Figures 2 and  3 ). This concentration was significantly cytotoxic and heralded the beginning of the steep part of the survival curve (Figure 3) . GSH depletion at the IC50value for EUP (1 h incubation) was about 25%. With 5, g ml -1 (13.8 nmol ml-1) EUP the surviving fraction was 1-2%, whereas about 70% of the GSH was still inside the cells after 1 h exposure to EUP.
Recently Arrick et al. (1983) published a study on four sesquiterpene lactones (vernolepin, helenalin, elephantopin and eriofertin). In their experiments lysis from tumour cells, measured by the release of 51Cr after incubation with the agents mentioned, was investigated. They showed that addition of BSO to P815 mastocytoma cells, during or immediately after 1 h exposure to 10 pg ml -I vernolepin, dramatically increased cytolysis. A 1.5 h delay in addition of BSO to such cells, which allowed them to resynthesise GSH, reduced cytolysis. They concluded that recovery of the GSH synthetic capacity after BSO treatment correlated with the loss of the synergistic effect of BSO on tumour cell susceptability to cytolysis of vernolepin.
Although these permeability studies were of a different nature from our clonogenic assays, the results obtained strengthen the view that GSH is involved in the cytostatic action of EUP. The importance for GSH synthesis at the time of EUP administration was also illustrated in our experiments, showing increased cytotoxicity of EUP after exposure of FIO 26 cells to BSO. GSH may serve to detoxify EUP before the alkylation of target molecules or restore sulphydryl reactive sites damaged by EUP.
Eupatoriopicrin in vivo
It was of interest to investigate whether the results obtained from the in vitro work could be extrapolated to the in vivo situation. For this purpose the effect of EUP on tumour growth was studied, using the Lewis lung carcinoma and the FIG26 fibrosarcoma, with and without pretreatment with BSO. The in vivo studies presented here confirm and extend our preliminary investigations performed with EUP, injected i.p. (Woerdenbag et al., 1987a, b) . EUP significantly inhibited tumour growth in Lewis lung and FIG26 bearing mice. In a previous report (Woerdenbag et al., 1988b) we showed that EUP caused a dose-dependent reduction of the GSH content in liver as well as in tumour tissue of C57BI mice. In these experiments 40 mg kg-1 EUP, injected i.v., caused a decrease of the GSH level in liver and tumour tissue to about 50% between 8 and 12 h after administration. Whereas there is a clear change in liver and tumour GSH levels on increasing the dosages of EUP from 20 to 40 mg kg-1, all dosages had the same effect on the growth A rapid, extensive and reversible GSH depletion by BSO in murine tissues, including several tumours, has been described previously in the dosage range of 1-5 mmol kg-1 i.p. (Griffith & Meister, 1979b; Minchinton et al., 1984; Lee et al., 1987) . In these studies hepatic GSH was depleted to about 20% of the control. The results that we found for normal liver, a reduction of about 50% of the control (Figure 6 ) is much less. This difference may possibly be explained by the different mouse species used in the different experiments.
As can be seen from Figures 6 and 7, there was a difference in sensitivity for BSO 4mmolkg-1 i.p. between the livers of differently treated mice. The livers of mice transplanted with the FIG 26 fibrosarcoma were as sensitive for GSH depletion as livers of healthy C57B1 mice. The GSH reduction in the liver of Lewis lung carcinoma bearing mice, however, was more profound and the recovery slower. The difference observed may possibly be explained by hepatic metastasis formation in Lewis lung carcinoma bearing animals (Mayo, 1972) .
The GSH levels in the two tumours have not been previously reported. The values for a number of transplantable murine tumours, as described in the literature (Minchinton et al., 1984; Lee et al., 1987) The basal GSH level and the absolute amount of GSH remaining at the nadir after BSO treatment was higher in the FIO 26 tumour than in the Lewis lung carcinoma. The growth of the FIO 26 tumour was stronger inhibited by EUP, with as well as without chemosensitisation by BSO. So it must be concluded that no direct relation exists between the percentage of GSH depletion in cells and cytostatic activity when different tumour systems are compared. Although speculative, an explanation for this phenomenon may possibly be a difference in levels of GSH-S-transferases in the Lewis lung tumour as compared with the FIO 26 tumour. The detoxification reaction of electrophilic compounds with GSH may proceed spontaneously or be catalyzed by GSH-S-transferases, after which the conjugates are converted to mercapturic acids and excreted into urine (Habig et al., 1974) . Increased GSH-S-transferase activity has been correlated with resistance of tumour cells to nitrogen mustards, a group of alkylating agents (Wang & Tew, 1985) . Other possibilities are differences in drug uptake and different levels of non-protein thiols, other than GSH and metallothioneins (Andrews et al., 1987) , as determinants for the ultimate antitumour effect.
It is expected that the therapeutic effect, when using BSO as a chemosensitiser, can be improved when GSH depletion is less in normal tissue, as compared with the tumour. Bone marrow is an example of normal tissue that has been found to be depleted by BSO to only moderate values (Russo et al., 1986; Soble & Dorr, 1987) . With the dosage regimen used in our experiments, GSH levels in the tumours were severely reduced by BSO at the moment of supplying EUP, while the GSH status of the liver was already recovering. This may partly explain the therapeutic benefit obtained. When combining BSO with 40 mg kg-1 EUP in FIO 26 bearing mice an extensive reduction of the GSH level was found. The accompanying severe GSH reduction in liver tissue was probably the cause for the acute toxicity following this combination. Recently, it has been shown that addition of BSO with certain sulphydryl-dependent anticancer agents may enhance acute toxicity in mice (Soble & Dorr, 1987) .
The finding that BSO treatment enhanced the action of EUP places the class of sesquiterpene lactones in the list of cytostatic agents that can be sensitised because of a reduced GSH level in tumour cells. BSO appeared to be an effective chemosensitiser for the anticancer drugs melphalan, cyclophosphamide, cisplatin, bleomycin and doxorubicin. Reviews on this topic have recently been published (Meister & Anderson, 1983; Arrick & Nathan, 1984) . However, cytostatics acting independently from GSH (5-fluorouracil, vincristine), are not potentiated by GSH depletion (Ozols & Cowan, 1986 ) and the effect of antineoplastic agents that require intracellular activation by sulphydryl groups (neocarzinostatin) is absent after GSH depletion (Russo et al., 1986) .
From the present study it can be concluded that GSH in tumour tissue plays an important role in the defence mechanism against the cytostatic action of EUP and thus may contribute to the maintenance of cellular integrity. GSH may decrease the cytotoxicity of EUP by facilitating its metabolism to less active compounds or by detoxification of EUP-induced free radicals or reactive oxygen intermediates. Recently, it was shown by us that EUP can elicit lipid peroxidation in liver and tumour tissue of the mouse. In this study it was suggested that GSH is important to maintain membrane integrity, because the EUP-induced oxidative degeneration of lipids from GSH depleted tissue was more profound (Woerdenbag et al., in preparation) . In a parallel study, we demonstrated that EUP caused DNA damage in Ehrlich ascites tumour cells. Also, this type of action was enhanced in cells depleted of GSH.
Adjuvant therapy with BSO, combined with sesquiterpene lactones, offers better therapeutic perspectives, especially because it has recently been found that certain semi-synthetic derivatives from EUP possessed stronger cytotoxic properties in vitro than the parent compound (Woerdenbag et al., 1988a) .
